查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
降血脂藥物市場：依藥物類別、按地區：市場規模、份額、前景、機會分析，2023-2030
市場調查報告書
商品編碼
1330165

降血脂藥物市場：依藥物類別、按地區：市場規模、份額、前景、機會分析，2023-2030

Antihyperlipidemic Drugs Market, By Drug Class, and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030
出版日期: | 出版商: Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

高血脂症包括各種遺傳性疾病和後天性疾病，這些疾病會增加血液中膽固醇和三酸甘油酯等脂質的濃度，從而增加心臟病和中風的風險，而心臟病和中風是全球範圍內導致死亡的主要原因。這是一個術語。 由於高血脂非常常見，因此世界各地對有助於降低高血脂和心血管疾病風險的降血脂藥物的需求不斷增長。

市場動態：

高脂血症盛行率的增加、久坐生活方式的迅速增加、老年人口的增加、降血脂藥物需求的增加以及新藥的推出正在導致世界範圍內降血脂人數的上升。這些是預計將增加成長的主要因素的藥品市場。

例如，根據美國中風協會的數據，中風是美國第五大死因和導致殘疾的主要原因。 美國每年有超過 795,000 人中風。 其中約 61 萬名患者患有首次或新發中風。

此外，根據《美國心臟協會雜誌》重新提交的報告，在歐洲，中風是最常見的死亡原因，也是成人殘疾的主要原因。 歐洲中風行動計畫 (SAP-E) 是一個泛歐洲項目，設定了到 2030 年基於證據的預防行動和中風服務的實施目標。

本研究的主要特點

  • 本報告對全球降血脂藥物市場進行了詳細分析，並以2022年為基準年估算了預測期（2023-2030年）的市場規模和年均增長率（CAGR%）。
  • 它也揭示了各個細分市場的潛在收入機會，並為該市場提供了一系列有吸引力的投資建議。
  • 它還提供了有關市場驅動因素、限制因素、機會、新產品發布和批准、市場趨勢、區域前景、主要參與者採取的競爭策略等的重要見解。
  • 根據以下參數對全球降血脂藥物市場的主要參與者進行了分析，例如公司亮點、產品組合、主要亮點、績效和策略。
  • 本研究涵蓋的主要公司包括賽諾菲 S.A.、輝瑞公司、Mylan N.V、安進公司、艾伯維公司、默克公司、雷迪博士實驗室有限公司、百時美施貴寶公司、阿斯利康有限公司和第一三共有限公司等。
  • 此報告的見解使行銷人員和公司主管能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
  • 《全球降血脂藥物市場報告》是針對該產業的各個利害關係人，例如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
  • 利害關係人可以透過用於分析全球降血脂藥物市場的各種策略矩陣來促進決策。

目錄

第1章研究目的與前提

  • 研究目的
  • 先決條件
  • 縮寫

第2章市場概述

  • 報告摘要
    • 市場定義和範圍
  • 執行摘要
  • 連貫的機會地圖 (COM)

第3章市場動態、法規與趨勢分析

  • 市場動態
    • 全球高血脂症盛行率不斷上升
    • 治療費用高且缺乏認識
    • 降血脂藥物的需求不斷增加
  • 影響分析
  • 主要亮點
  • 監管場景
  • 產品發布/核准
  • PEST分析
  • 波特的分析
  • 合併/收購場景

第 4 章全球降血脂藥物市場 - 冠狀病毒 (COVID-19) 大流行的影響

  • COVID-19 的流行病學
  • 供給面與需求面分析
  • 經濟影響

第5章全球降血脂藥物市場：依藥物類別劃分，2023-2030

  • 他汀類藥物
  • 膽汁酸分泌抑制劑
  • 膽固醇吸收抑制劑
  • 原纖維酸衍生物
  • PCSK9抑制劑
  • 複方藥物
  • 其他

第6章全球降血脂藥市場：依地區劃分，2023-2030

  • 北美
  • 拉丁美洲
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第7章競爭態勢

  • Sanofi S.A.
  • Pfizer Inc.
  • Mylan N.V.
  • Amgen Inc.
  • Abbvie Inc.
  • Merck & Co., Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Bristol-Myers Squibb Company
  • AstraZeneca plc
  • Daiichi Sankyo Company

第 8 章部分

  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI5992

Hyperlipidemia is a term that encompasses various genetic and acquired disorders that describe an elevated lipid levels, such as cholesterol and triglycerides, in the blood, which in turn increases the risk of heart disease and stroke, the leading cause of death worldwide. It is a very common disorder, and thus, there is an increasing demand for antihyperlipidemic drugs across the world, as they help reduce the risk of hyperlipidemia and cardiovascular diseases.

Market Dynamics:

Increasing prevalence of hyperlipidemia, surge in sedentary lifestyle, growing geriatric population, increasing demand for antihyperlipidemic drugs, and introduction of novel drugs are major factors expected to augment the growth of the global antihyperlipidemic drugs market.

For instance, according to the American Stroke Association, stroke is the No. 5 cause of death and a leading cause of disability in the United States. Every year, more than 795,000 people in the U.S. have a stroke. About 610,000 of these are first or new strokes.

Moreover, according to the repost by AHA Journals, in Europe, stroke is the most common cause of death as well as a leading cause of adult disability. The Stroke Action Plan for Europe (SAP-E) is a pan-European project that sets targets for the implementation of an evidence-based preventive actions and stroke services until 2030.

Key features of the study:

  • This report provides in-depth analysis of the global antihyperlipidemic drugs market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global antihyperlipidemic drugs market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Sanofi S.A., Pfizer Inc., Mylan N.V, Amgen Inc., Abbvie Inc., Merck & Co., Inc., Dr. Reddy's Laboratories Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, and Daiichi Sankyo Company, Limited, among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global antihyperlipidemic drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antihyperlipidemic drugs market.

Detailed Segmentation:

  • Global Antihyperlipidemic Drugs Market, By Drug Class:
    • Statins
    • Bile Acid Sequestrants
    • Cholesterol Absorption Inhibitors
    • Fibric Acid Derivatives
    • PCSK9 Inhibitors
    • Combination
    • Others
  • Global Antihyperlipidemic Drugs Market, By Geography:
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
  • Company Profiles:
    • Sanofi S.A.
    • Pfizer Inc.
    • Mylan N.V.
    • Amgen Inc.
    • Abbvie Inc.
    • Merck & Co., Inc.
    • Reddy's Laboratories Ltd.
    • Bristol-Myers Squibb Company
    • AstraZeneca plc
    • Daiichi Sankyo Company, Limited, among others.

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Class
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Increasing prevalence of hyperlipidemia worldwide
    • High cost of treatment and lack of awareness
    • Increasing demand for antihyperlipidemic drugs
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Antihyperlipidemic Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Antihyperlipidemic Drugs Market, By Drug Class, 2023-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Statins
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Bile Acid Sequestrants
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Cholesterol Absorption Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Fibric Acid Derivatives
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • PCSK9 Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Combination
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)

6. Global Antihyperlipidemic Drugs Market, By Region, 2023-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)

7. Competitive Landscape

  • Sanofi S.A.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Mylan N.V.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Amgen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Abbvie Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Merck & Co., Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Dr. Reddy's Laboratories Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bristol-Myers Squibb Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AstraZeneca plc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Daiichi Sankyo Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Analyst Views

8. Section

  • Research Methodology
  • About us